India's Glenmark Pharma announces discovery of new monoclonal antibody
MUMBAI Feb 4 (Reuters) - Indian drugmaker Glenmark Pharmaceuticals said on Monday it has discovered a new molecule that can be used to treat diseases such as rheumatoid arthritis and inflammatory bowel disease.
The new molecule, named GBR 830, is an anti-OX40 monoclonal antibody, Glenmark said in a statement, adding that OX40 is responsible for some autoimmune diseases.
The company said it has initiated studies for an investigational new drug (IND) application to be filed with the U.S. Food and Drug Administration. (Reporting by Kaustubh Kulkarni in Mumbai; Editing by Jijo Jacob)
- U.S. Mega Millions lottery up to $400 million, 2nd-biggest ever
- Pope Francis named Time's Person of the Year |
- Uruguay becomes first country to legalize marijuana trade
- Thousands of South Africans line up to see Mandela lie in state |
- China bitcoin arbitrage ends as traders work around capital controls